Company profile: Flare Therapeutics
1.1 - Company Overview
Company description
- Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
Products and services
- Discovery Engine: A modular platform that integrates genetic, biochemical, and chemical insights to pinpoint druggable pockets in transcription factors, enabling creation of small molecule modulators
- FX-909: A first-in-class small molecule inhibitor of transcription factor PPARG, in Phase 1 evaluation for advanced solid malignancies, including advanced urothelial carcinoma
- Pipeline of Drug Programs: A scalable collection targeting transcription factors with genetic and biological validation, initially in precision oncology and extending to metabolic, neurology, immunology/inflammation, and rare genetic disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Flare Therapeutics
DYSIS Medical
HQ: United Kingdom
Website
- Description: Provider of medical imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions, including the DYSIS Colposcope for imaging the cervix and lower genital tract with adjunctive acetowhitening display; DYSISmap to quantify acetowhitening and overlay a color-coded map to assist biopsy targeting; and DYSIS SMARTtrack for enhanced documentation with high-resolution images, video, and instant exam playback.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DYSIS Medical company profile →
Diatech Pharmacogenetics
HQ: Italy
Website
- Description: Provider of pharmacogenetics tests and precision medicine diagnostic solutions: Real Time PCR for variants of clinical interest in solid tumors and infectious diseases; Next Generation Sequencing equipment, libraries, and bioinformatics for SNPs, In/Del, CNV, and gene fusions in solid tumors; Pyrosequencing and fragment analysis for somatic or germline variants; and oncology equipment, kits, and software for analysis using MassArray technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diatech Pharmacogenetics company profile →
Celcuity
HQ: United States
Website
- Description: Provider of oncology therapeutics and cellular analysis solutions, including gedatolisib, an investigational pan-PI3K/mTOR inhibitor for advanced breast cancer and metastatic castration-resistant prostate cancer; the CELsignia platform to measure signal transduction in live tumor cells and identify tumor drivers and potential first-in-class targeted therapies; and an Expanded Access Program for patients from closed clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celcuity company profile →
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
Remix Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule medicines and an RNA-processing drug discovery platform. Offers REMaster to design modulators, supported by machine-learning data science on a transcriptome database, biology and biomolecular sciences with multiplexed HT screening, and medicinal/computational chemistry. Pipeline targets oncology and neurodegeneration, including REM-422, an mRNA degrader targeting MYB for ACC and AML, in Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remix Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Flare Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Flare Therapeutics
2.2 - Growth funds investing in similar companies to Flare Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Flare Therapeutics
4.2 - Public trading comparable groups for Flare Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →